BR112022018173A2 - Composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, composto para o uso e uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo - Google Patents
Composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, composto para o uso e uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmoInfo
- Publication number
- BR112022018173A2 BR112022018173A2 BR112022018173A BR112022018173A BR112022018173A2 BR 112022018173 A2 BR112022018173 A2 BR 112022018173A2 BR 112022018173 A BR112022018173 A BR 112022018173A BR 112022018173 A BR112022018173 A BR 112022018173A BR 112022018173 A2 BR112022018173 A2 BR 112022018173A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989104P | 2020-03-13 | 2020-03-13 | |
| PCT/EP2021/056393 WO2021180952A1 (en) | 2020-03-13 | 2021-03-12 | Fused pyrimidine compounds as kcc2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018173A2 true BR112022018173A2 (pt) | 2022-10-25 |
Family
ID=74874882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018173A BR112022018173A2 (pt) | 2020-03-13 | 2021-03-12 | Composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, composto para o uso e uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo |
Country Status (25)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022407047A1 (en) * | 2021-12-08 | 2024-07-25 | Kineta, Inc. | Bicyclic heteroarenes and methods of their use |
| CN117843618A (zh) * | 2022-08-29 | 2024-04-09 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
| CN121241048A (zh) * | 2023-04-05 | 2025-12-30 | 艾索尼斯治疗公司 | Kcc2增强剂及其用途 |
| US20260191874A1 (en) * | 2024-03-06 | 2026-07-09 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of autism spectrum disorder, obsessive compulsive disorder and tics |
| WO2025188955A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of psychosis and psychotic disorders |
| WO2025188977A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of addiction and insomnia |
| WO2025188976A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of neurodegenerative disorders |
| US20250281498A1 (en) * | 2024-03-06 | 2025-09-11 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies |
| WO2025188973A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of 22q11.2 deletion/duplication syndromes |
| WO2025188951A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of seizure disorders |
| WO2025188953A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of neuropathic and neuro-inflammatory pain |
| WO2025188979A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds and pridopidine for treatment of huntington's disease |
| US20260108529A1 (en) * | 2024-10-23 | 2026-04-23 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of tinnitus, acute sensorineural hearing loss, age-related hearing loss, and meniere's disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3398152B2 (ja) | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体 |
| US20090099195A1 (en) * | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| RS53382B (sr) | 2008-08-20 | 2014-10-31 | Zoetis Llc | Jedinjenja pirol [2,3-d]pirimidina |
| AR079814A1 (es) * | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| US9340540B2 (en) | 2014-02-28 | 2016-05-17 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| WO2018217766A1 (en) | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
| JP7399848B2 (ja) * | 2017-09-01 | 2023-12-18 | カドモン コーポレイション，リミティド ライアビリティ カンパニー | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 |
| KR20210050493A (ko) * | 2018-05-25 | 2021-05-07 | 더 칠드런스 메디칼 센터 코포레이션 | 척수 손상의 치료 방법 |
-
2021
- 2021-03-12 RS RS20231022A patent/RS64823B1/sr unknown
- 2021-03-12 KR KR1020227035465A patent/KR20220152319A/ko not_active Ceased
- 2021-03-12 SI SI202130073T patent/SI4103566T1/sl unknown
- 2021-03-12 FI FIEP21712145.8T patent/FI4103566T3/fi active
- 2021-03-12 JP JP2022554784A patent/JP7793529B2/ja active Active
- 2021-03-12 PT PT217121458T patent/PT4103566T/pt unknown
- 2021-03-12 EP EP21712145.8A patent/EP4103566B1/en active Active
- 2021-03-12 PE PE2022001943A patent/PE20230106A1/es unknown
- 2021-03-12 AU AU2021234134A patent/AU2021234134B2/en active Active
- 2021-03-12 PL PL21712145.8T patent/PL4103566T3/pl unknown
- 2021-03-12 CN CN202411881248.3A patent/CN119684299A/zh active Pending
- 2021-03-12 HU HUE21712145A patent/HUE064037T2/hu unknown
- 2021-03-12 CN CN202411881483.0A patent/CN119735594A/zh active Pending
- 2021-03-12 BR BR112022018173A patent/BR112022018173A2/pt unknown
- 2021-03-12 ES ES21712145T patent/ES2962136T3/es active Active
- 2021-03-12 MX MX2022011354A patent/MX2022011354A/es unknown
- 2021-03-12 IL IL296265A patent/IL296265B2/en unknown
- 2021-03-12 WO PCT/EP2021/056393 patent/WO2021180952A1/en not_active Ceased
- 2021-03-12 US US17/911,051 patent/US12617795B2/en active Active
- 2021-03-12 CA CA3171192A patent/CA3171192A1/en active Pending
- 2021-03-12 CN CN202180020856.3A patent/CN115298182B/zh active Active
- 2021-03-12 LT LTEPPCT/EP2021/056393T patent/LT4103566T/lt unknown
- 2021-03-12 SM SM20230384T patent/SMT202300384T1/it unknown
- 2021-03-12 DK DK21712145.8T patent/DK4103566T3/da active
- 2021-03-12 CN CN202411881526.5A patent/CN119684300A/zh active Pending
- 2021-03-12 HR HRP20231314TT patent/HRP20231314T1/hr unknown
-
2022
- 2022-09-01 CL CL2022002386A patent/CL2022002386A1/es unknown
- 2022-09-09 CO CONC2022/0012884A patent/CO2022012884A2/es unknown
-
2025
- 2025-09-12 JP JP2025151939A patent/JP2025186368A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
| BRPI0908353B8 (pt) | composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica | |
| BR112021023347A2 (pt) | Compostos de pirrolidina | |
| BR112022002496A2 (pt) | Compostos deuterados para uso no tratamento de câncer | |
| UY39029A (es) | Uso de compuestos de aminopropionato sustituido en el tratamiento de la infección por sars-cov-2 | |
| BR112018008397A2 (pt) | derivados de di-hidroimidazopirazinona úteis no tratamento do câncer | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| BRPI0410037B8 (pt) | inibidores de fosfatidilinositol 3-cinase, sua composição farmacêutica, e seu uso | |
| BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
| BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
| BRPI0517634A (pt) | derivado de tiazol ou um derivado farmaceuticamente aceitável do mesmo, processo para a preparação de um composto, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BRPI0408767B8 (pt) | inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica | |
| BR112022003562A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos | |
| BR112022001567A2 (pt) | Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias. | |
| BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
| BRPI0406717A (pt) | Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção | |
| BRPI0409498A (pt) | uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto | |
| BRPI0719920B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário | |
| BRPI0513858B8 (pt) | compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende | |
| BR112021019817A2 (pt) | Compostos de pirrol | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| BR112023002077A2 (pt) | Composto e seu uso, composição e formulação farmacêutica | |
| BR112022017779A2 (pt) | Imunomodulação de azaletos de o-het-arila | |
| BR112021002565A8 (pt) | Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto | |
| BRPI0416238A (pt) | compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, uso dos compostos e métodos para o tratamento e/ou a prevenção de doenças que são moduladas por ppar(delta) e/ou agonistas ppar(alfa) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |